Published on February 2, 2010 at 11:10 PM
Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets:
TAROF) reported today that it has received approval from the U.S. Food
and Drug Administration (“FDA”) for its Abbreviated New Drug Application
(“ANDA”) for Levetiracetam Tablets, 250 mg, 500 mg, 750 mg and 1000 mg
(“levetiracetam tablets”).
Taro’s levetiracetam tablets is a prescription product used in the
treatment of epilepsy, and is bioequivalent to UCB’s Keppra® Tablets.
According to industry sources, levetiracetam tablets had U.S. sales of
over $700 million in 2009.
SOURCE Taro Pharmaceutical Industries